GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK
The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
GLP-1 receptor (GLP-1R) is widely located throughout the brain, but the precise molecular mechanisms mediating the actions of GLP-1 and its long-acting analogs on adipose tissue as well as the brain areas responsible for these interactions remain largely unknown. We found that central injection of a clinically used GLP-1R agonist, liraglutide, in mice stimulates brown adipose tissue (BAT) thermogenesis and adipocyte browning independent of nutrient intake. The mechanism controlling these actions is located in the hypothalamic ventromedial nucleus (VMH), and the activation of AMPK in this area is sufficient to blunt both central liraglutide-induced thermogenesis and adipocyte browning. The decreased body weight caused by the central injection of liraglutide in other hypothalamic sites was sufficiently explained by the suppression of food intake. In a longitudinal study involving obese type 2 diabetic patients treated for 1 year with GLP-1R agonists, both exenatide and liraglutide increased energy expenditure. Although the results do not exclude the possibility that extrahypothalamic areas are also modulating the effects of GLP-1R agonists, the data indicate that long-acting GLP-1R agonists influence body weight by regulating either food intake or energy expenditure through various hypothalamic sites and that these mechanisms might be clinically relevant.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beiroa (36) et al. injected GLP-1 analog, liraglutide (LIR), into mice. LIR was found to stimulate the thermogenesis of brown adipose tissue and the browning of adipose cells, independent of the intake of nutrients. It can increase the thermogenesis and utilization of triacylglycerol-derived fatty acids and glucose in brown adipocytes and reduce the lipid content through the central GLP-1R agonist”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [36]
In the citing paper
“Nevertheless, the results showed reduced or unaltered REE in both studies after treatment with GLP-1 Ras, as opposed to the first studies, where GLP-1 RAs led to a raised REE, mainly when adjusted for fat-free mass [101].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [101]
In the citing paper
“Furthermore, a central injection of liraglutide in mice stimulated thermogenesis of BAT and browning of white adipocytes independently of nutrient intake [176].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [176]
In the citing paper
“In particular, feeding activates the secretion of periprandial gut hormones, such as CCK, GLP‐1, or secretin 105, 106, 107.”
From Inter‐organ communication: a gatekeeper for metabolic health (2019) · cites this paper as [105]
Citations
Cites
Identification and Importance of Brown Adipose Tissue in Adult Humans
Cypess, A. M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A. B., Kuo, F. C., Palmer, E. L., Tseng, Y.-H., Doria, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810780 · Cited by 4,399
Cold-Activated Brown Adipose Tissue in Healthy Men
van Marken Lichtenbelt, W. D., Vanhommerig, J. W., Smulders, N. M., Drossaerts, J. M. A. F. L., Kemerink, G. J., Bouvy, N. D., Schrauwen, P., & Teule, G. J. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808718 · Cited by 3,452
Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human
Wu, J., Boström, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A.-H., Khandekar, M., Virtanen, K. A., Nuutila, P., Schaart, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.016 · Cited by 3,319
Functional Brown Adipose Tissue in Healthy Adults
Virtanen, K. A., Lidell, M. E., Orava, J., Heglind, M., Westergren, R., Niemi, T., Taittonen, M., Laine, J., Savisto, N.-J., Enerbäck, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808949 · Cited by 3,058
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“In agreement with previous findings (7,17,18), we found that the central stimulation of GLP-1R reduces food intake and body weight.”
BackgroundResultInfluentialGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Among its numerous physiological effects (3), GLP-1 increases insulin and decreases glucagon secretion in a glucose-dependent manner (4,5), slows gastric emptying (6), increases glucose disposal, and decreases appetite (7).”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 9×
“In addition to the functional data on liraglutide from the mouse study, we analyzed data from a cohort of obese patients with T2D who had been treated for 1 year with the antidiabetic drugs metformin and metformin in combination with the GLP-1R agonists exenatide and liraglutide (Table 1).”
BackgroundInfluentialPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 1×
“Among its numerous physiological effects (3), GLP-1 increases insulin and decreases glucagon secretion in a glucose-dependent manner (4,5), slows gastric emptying (6), increases glucose disposal, and decreases appetite (7).”
BackgroundAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Cited by
Items 301–400 of 598
Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats
Model, J. F. A., Lima, M. V., Ohlweiler, R., Vogt, É. L., Rocha, D. S., de Souza, S. K., Türck, P., Araújo, A. S. D. R., & Vinagre, A. S. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111158 · Cited by 24
Subedi, L., Bamjan, A. D., Phuyal, S., Shim, J., Cho, S., Seo, J. B., Chang, K.-Y., Byun, Y., Kweon, S., & Park, J. W. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.039 · Cited by 22
Gaggini, M., Sabatino, L., Suman, A. F., Chatzianagnostou, K., & Vassalle, C. (2025) · Cells · doi:10.3390/cells14050387 · Cited by 35
“…and liraglutide) appear effective in modulating BAT thermo-genesis and browning, controlling food intake, and increasing energy expenditure through the action on the hypothalamic AMPK pathway, with clinically significant effects; therefore, they are very promising in the obesity setting [40].”
Molecular mechanisms of appetite and obesity: a role for brain AMPK
de Morentin, P. B. M., Urisarri, A., Couce, M. L., & López, M. (2016) · Clinical Science · doi:10.1042/cs20160048 · Cited by 22
Gaspar, R. S., Delafiori, J., Zuccoli, G. S., Carregari, V. C., do Prado, T. P., Morari, J., Sidarta-Oliveira, D., Solon, C., Catharino, R. R., ARAUJO, E. P. D., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00231.2022 · Cited by 22
Newer antidiabetic drugs and calorie restriction mimicry
Jacob, J. J., Kalra, S., & Gupta, Y. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.172242 · Cited by 23
“[14] Liraglutide is known to inhibit AMPK in the hypothalamus, causing satiety, and browning of white adipose tissue;[15] as well as in the pancreatic beta-cells, leading to improved beta-cell survival.”
BackgroundHarmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis
Nie, T., Hui, X., Mao, L.-F., Nie, B.-M., Li, K., Sun, W., Gao, X.-F., Tang, X., Xu, Y., Jiang, B.-S., et al. (2016) · Scientific Reports · doi:10.1038/srep36382 · Cited by 18
AMPK and the Need to Breathe and Feed: What’s the Matter with Oxygen?
Evans, A. M., & Hardie, D. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103518 · Cited by 22
“Thus, direct administration to VMH by intracerebroventricular injection of the female sex hormone estradiol [141], the thyroid hormone T3 [142], the GLP-1 receptor agonist liraglutide [143] or Bone Morphogenetic Protein-8B (BMP8B) [144,145] all reduced phosphorylation of AMPK in VMH and increased thermogenesis.”
BackgroundCentral nervous system regulation of intestinal lipid and lipoprotein metabolism
Farr, S., Taher, J., & Adeli, K. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000254 · Cited by 21
Hypothalamic AMP-Activated Protein Kinase as a Whole-Body Energy Sensor and Regulator
Min, S. H., Song, D. K., Lee, C. H., Roh, E., & Kim, M. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1922 · Cited by 33
“Targeted injection of the GLP-1 receptor agonists exendin-4 or lira-glutide into the VMH has been found to decrease food intake in mice and humans [68,69].”
BackgroundKlingenspor, M., Bast‐Habersbrunner, A., Bolze, F., Li, Y., Maurer, S., Schweizer, S., Willershäuser, M., & Fromme, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-52031-5_4 · Cited by 32
Zhao, Y.-F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.956277 · Cited by 29
Dischinger, U., Kötzner, L., Kovatcheva‐Datchary, P., Kleinschmidt, H., Haas, C., Perez, J., Presek, C., Koschker, A., Miras, A. D., Hankir, M. K., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155341 · Cited by 22
“Effects of GLP-1 and PYY are mainly mediated via the hypothalamus [33,34], which is the key integrator of peripheral and central signals controlling energy balance and food intake are necessary for the efficiency of bariatric surgery.”
The impact of metabolic endotoxaemia on the browning process in human adipocytes
Omran, F., Murphy, A. M., Younis, A. Z., Kyrou, I., Vrbíková, J., Hainer, V., Šrámková, P., Fried, M., Ball, G., Tripathi, G., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02857-z · Cited by 22
“GLP-1 and β3-adrenergic receptor agonists, such as Liraglutide and Mirabegron, result in BAT activation and have been shown to reduce fat mass [48, 49].”
BackgroundNeonatal GLP1R activation limits adult adiposity by durably altering hypothalamic architecture
Rozo, A. V., Babu, D. A., Suen, P. A., Groff, D., Seeley, R. J., Simmons, R. A., Seale, P., Ahima, R. S., & Stoffers, D. A. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.05.006 · Cited by 20
The molecular basis for current targets of NASH therapies
Qureshi, K., & Neuschwander‐Tetri, B. A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1703949 · Cited by 23
“Secreted from enteroendocrine cells in the small intestine in response to luminal contents and also circulating bile acids via TGR5, circulating GLP-1 is an activator of peripheral energy disposal, including activation of brown adipose tissue [56].”
BackgroundNeuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 30
Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus
Lee, J., Kim, R., Kim, M.-H., Lee, S.-H., Cho, J.-H., Lee, J. M., Jang, S.-A., & Kim, H.-S. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.006 · Cited by 20
Stafeev, I., Agareva, M. Y., Michurina, S. S., Tomilova, A., Shestakova, E. A., Zubkova, E., Sineokaya, M. S., Ratner, E. I., Menshikov, M. Y., Parfyonova, Y. V., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176476 · Cited by 23
Takeda, K., Sawazaki, H., Takahashi, H., Yeh, Y., Jheng, H., Nomura, W., Ara, T., Takahashi, N., Seno, S., Osato, N., et al. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12498 · Cited by 23
Tapía, P., Fernández‐Galilea, M., Robledo, F., Mardones, P., Galgani, J. E., & Cortés, V. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12389 · Cited by 22
Beaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 24
“nucleus attenuated the liraglutide-mediated BAT activation (63).”
Nonogaki, K., & Kaji, T. (2018) · Journal of Diabetes Research · doi:10.1155/2018/6482958 · Cited by 20
“mediated brown adipose tissue thermogenesis and adipocyte browning independent of food intake in mice [18].”
BackgroundQuagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 23
“Notably, the reduction in glucose levels contributes to reduced visceral fat and white adipose tissue (WAT), and to an increase in brown adipose tissue (BAT) [35,36], leading to reduced cardio-metabolic and atherosclerotic risk [37,38].”
Rodríguez, R., Hergarden, A. C., Krishnan, S., Morales, M., Lam, D., Tracy, T., Tang, T., Patton, A., Lee, C. R., Pant, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102156 · Cited by 34
Park, S., Oh, S., & Kim, E. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102682 · Cited by 20
“Liraglutide mimicked caloric restriction in mice, resulting in dramatic anorexia and weight loss in our study and others (20,21,36).”
BackgroundPharmacological modulation of adaptive thermogenesis: new clues for obesity management?
Genchi, V. A., Palma, G., Sorice, G. P., D’Oria, R., Caccioppoli, C., Marrano, N., Biondi, G., Caruso, I., Cignarelli, A., Natalicchio, A., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02125-0 · Cited by 23
“Human – – ↑ EE [30] ↓ body weight [30] ↑ BAT glucose uptake [169] –”
BackgroundInfluentialGiralt, M., Cairó, M., & Villarroya, F. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.08.005 · Cited by 21
Self-citationMaio, G. D., Alessio, N., Demirsoy, İ. H., Peluso, G., Perrotta, S., Monda, M., & Bernardo, G. D. (2021) · Cells · doi:10.3390/cells10020403 · Cited by 21
“GLP-1, through its receptor GLP-1R, promotes insulin production and glucagon reduction release, and it may stimulate brown fat thermogenesis [46].”
BackgroundTranscriptional control and hormonal response of thermogenic fat
Emont, M. P., Yu, H. M., & Wu, J. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0026 · Cited by 19
“…for example a glucagon-like peptide-1 (GLP1) receptor agonist works in the CNS to activate brown adipose tissue and may increase resting energy expendi- ture in humans (Beiroa et al. 2014). b-adrenergic signaling may not be the only pathway for cold-induced activation of thermogenic fat.”
BackgroundInteractions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism
Model, J. F. A., Normann, R. S., Vogt, É. L., Dentz, M. C. V., de Amaral, M., Xu, R., Bachvaroff, T. R., Spritzer, P. M., Chung, J. S., & Vinagre, A. S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116623 · Cited by 22
Dongdem, J. T., Etornam, A. E., Beletaa, S., Alidu, I., Kotey, H., & Wezena, C. A. (2024) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2024/2005589 · Cited by 26
Zhang, A., Liu, Q., Xiong, Y., Li, J., Xu, Y., Song, H., Jing, X., Xu, H., Yang, N., Li, Y., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16294 · Cited by 22
“11,34 Recent studies found that dysregulation of substrate utilization plays a pivotal role in the pathogenesis of metabolic diseases including obesity.”
Al‐Soleiti, M., Leung, J. G., Mubaydeen, T., Markota, M., Abulseoud, O. A., Singh, B., & Sola, C. L. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002090 · Cited by 24
Li, Y., Liu, X., Li, G., & Zhang, P. (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00820-9 · Cited by 19
“It is helpful to turn white fat tissue into brown fat tissue and stimulate brown fat tissue thermogenesis induced by liraglutide [34].”
BackgroundGLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions
Li, H., Donelan, W., Wang, F., Zhang, P., Yang, L., Ding, Y., Tang, D., & Li, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.777026 · Cited by 21
“, 2016), while stimulating the browning and lipolysis ofWAT (Bostrom et al., 2012; Lockie et al., 2012; Beiroa et al., 2014).”
BackgroundChan, P., & Hsieh, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169448 · Cited by 20
“For instance, gut hormones could activate BAT through their effects on the efferent SNS tone, such as cholecystokinin (CCK) [68,69] and glucagon-like peptide (GLP-1) [70].”
BackgroundXie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Genetic Targeting of GRP78 in the VMH Improves Obesity Independently of Food Intake
Liñares‐Pose, L., Rial‐Pensado, E., Estévez‐Salguero, Á., Milbank, E., González‐García, I., Rodríguez, C., Seoane‐Collazo, P., Martínez‐Sánchez, N., Nogueiras, R., Prieto, D., et al. (2018) · Genes · doi:10.3390/genes9070357 · Cited by 20
Self-citationReprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.009 · Cited by 21
Self-citationDe Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“Nevertheless, the results showed reduced or unaltered REE in both studies after treatment with GLP-1 Ras, as opposed to the first studies, where GLP-1 RAs led to a raised REE, mainly when adjusted for fat-free mass [101].”
ResultEngineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
The crosstalk between BAT thermogenesis and skeletal muscle dysfunction
Chen, Y., Hu, Q., Wang, C., & Wang, T. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1132830 · Cited by 19
Tudurí, E., Beiroa, D., Porteiro, B., López, M., Diéguez, C., & Nogueiras, R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12488 · Cited by 19
Self-citationXie, C., Wang, X., Jones, K. L., Horowitz, M., Sun, Z., Little, T. J., Rayner, C. K., & Wu, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13906 · Cited by 19
Ni, W., & Shi, X. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.06.121 · Cited by 18
Epicardial Adipose Tissue—A Novel Therapeutic Target in Obesity Cardiomyopathy
Wiszniewski, K., Grudniewska, A., Szabłowska‐Gadomska, I., Pilichowska‐Paszkiet, E., Zaborska, B., Zgliczyński, W., Dudek, P., Bik, W., Sota, M., & Mrozikiewicz‐Rakowska, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167963 · Cited by 25
“In addition, GLP-1R activation has been shown to stimulate brown adipose tissue thermogenesis and beneficial white-to-brown conversion of adipose tissue in murine models [147].”
Forest, C. D., Joffin, N., Jaubert, A., & Noirez, P. (2016) · Adipocyte · doi:10.1080/21623945.2016.1187345 · Cited by 20
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 17
“To that end, GLP-1 RAs might be useful in light of studies demonstrating EAT reductions following treatment with dulaglutide, liraglutide or semaglutide (Yang et al., 2013; Beiroa et al., 2014; Iacobellis et al., 2017; Iacobellis and Villasante Fricke, 2020; Rasmussen et al., 2021).”
BackgroundAlZaim, I., Eid, A. H., Abd‐Elrahman, K. S., & EL‐Yazbi, A. F. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115337 · Cited by 16
Brown, J. D., McAnally, D., Ayala, J. E., Burmeister, M. A., Morfa, C. J., Smith, L. H., & Ayala, J. E. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00459.2017 · Cited by 20
Neuroendocrine drivers of risk and resilience: The influence of metabolism & mitochondria
Turkson, S., Kloster, A., Hamilton, P. J., & Neigh, G. N. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100770 · Cited by 18
“In mice and rats, central activation of GLP-1R or activation of GLP-1R in the VMH respectively, led to increased UCP1 expression causing the “browning” of white adipose tissue (Beiroa et al., 2014).”
BackgroundPoly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“Some animal studies report positive effects [43, 44], and others do not [45, 46].”
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Doukbi, E., Ancel, P., Dutour, A., Soghomonian, A., Ahmed, S., Castejon, V., Pipéroglou, C., Gariboldi, V., Lenoir, M., Lechevallier, É., et al. (2024) · Obesity · doi:10.1002/oby.24023 · Cited by 16
Horizons in the Pharmacotherapy of Obesity
Arch, J. R. S. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0177-4 · Cited by 17
Differential Role of Hypothalamic AMPKα Isoforms in Fish: an Evolutive Perspective
Conde‐Sieira, M., Capelli, V., Álvarez‐Otero, R., Comesaña, S., Liñares‐Pose, L., Velasco, C., López, M., & Soengas, J. L. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1434-9 · Cited by 16
Circulating GLP-1 in infants born small-for-gestational-age: breast-feeding versus formula-feeding
Díaz, M., Bassols, J., Sebastiani, G., López‐Bermejo, A., Ibáñez, L., & de Zegher, F. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.117 · Cited by 15
Seoane‐Collazo, P., Romero, A., Rial‐Pensado, E., Liñares‐Pose, L., Estévez‐Salguero, Á., Fernø, J., Nogueiras, R., Diéguez, C., & López, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041515 · Cited by 16
Self-citationAdipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 15
“Thus, administration of GLP-1R agonists into the hypothalamic ventromedial nucleus increases sympathetic nervous system activity leading to enhancement of BAT thermogenesis and brown - ing of WAT [120 ].”
Self-citationRai, C., & G., P. P. C. (2023) · European Journal of Nutrition · doi:10.1007/s00394-023-03162-4 · Cited by 15
Molecular and cellular regulation of thermogenic fat
Wang, C., Wang, X., & Hu, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1215772 · Cited by 15
Zhao, L. Q., Li, W., Zhang, P., Wang, D., Yang, L., & Yuan, G. (2024) · Endocrine · doi:10.1007/s12020-024-03734-2 · Cited by 17
“Central administration of liraglutide was veri fi ed to activate BAT thermogenesis and brown epididymal WAT by decreasing hypothalamic AMPK activity [18].”
Moreno, Ó., Reyes‐García, R., Pardo, I. M., López-Martínez, M., & Soler, M. J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae039 · Cited by 15
“Conversely, GLP1 indirectly promotes BAT activation and thermogenesis via central nervous system pathways in animals [29 ].”
BackgroundGarcía‐Vega, D., Cinza‐Sanjurjo, S., Eirás, S., & González‐Juanatey, J. R. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.04.032 · Cited by 17
Emont, M. P., Essene, A. L., Gulko, A., Bozadjieva-Kramer, N., Jacobs, C. L., Nagesh, S., Seeley, R. J., Tsai, L. T.-Y., & Rosen, E. D. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102126 · Cited by 15
“…Cidea adipocytes, which express a number of thermogenic markers in speci fi cally found in the ING Sema samples cluster with beige adipocytes induced by cold exposure from Holman et al. [21], consistent with previous reports that GLP-1 agonism activates thermogenesis [22] (Extended Data Figure 9).”
Physiological regulation and metabolic role of browning in white adipose tissue
Janković, A., Otašević, V., Stančić, A., Buzadžić, B., Korać, A., & Korać, B. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0034 · Cited by 15
“The glucagon-like peptide-1 (GLP-1) is an incretin hormone released from ileum and colon in response to caloric intake [151] and it stimulates BAT thermogenesis through hypothalamus [152].”
BackgroundWang, X., Ma, B., Chen, J., You, H., Sheng, C., Yang, P., & Qu, S. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6620289 · Cited by 16
“Additionally, a previous study showed that GLP-1R agonist stimulates BAT thermogenesis and adipocyte browning independent of nutrient intake in mice [34].”
BackgroundCrosstalk between adipose tissue and the microbiota-gut-brain axis in metabolic diseases
Yu, Z.-W., Wang, Y., Yu, Z. H., Lu, M., & Xu, B. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68786 · Cited by 21
Rodrigues, V. S. T., de Moura, E. G., Peixoto, T. C., Soares, P. N., Lopes, B. P., Bertasso, I. M., Silva, B. S. D., Cabral, S. S., Kluck, G. E. G., Atella, G. C., et al. (2022) · Physiological Reports · doi:10.14814/phy2.15191 · Cited by 14
“The central role of GLP1 has been investigated as a therapeutic target in obesity (Beiroa et al., 2014; Grill, 2020; Terrill et al., 2016).”
BackgroundPhysiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals
Model, J. F. A., Rocha, D. S., Fagundes, A. D. C., & Vinagre, A. S. (2022) · Veterinary and Animal Science · doi:10.1016/j.vas.2022.100245 · Cited by 18
Adiposity-Related Cancer and Functional Imaging of Brown Adipose Tissue
Santhanam, P., Sólnes, L. B., Hannukainen, J. C., & Taïeb, D. (2015) · Endocrine Practice · doi:10.4158/ep15870.ra · Cited by 15
Asperlin Stimulates Energy Expenditure and Modulates Gut Microbiota in HFD-Fed Mice
Wu, C., Zhou, Y., Qi, G., Liu, D., Cao, X., Yu, J., Zhang, R., Lin, W., & Guo, P. (2019) · Marine Drugs · doi:10.3390/md17010038 · Cited by 15
“Many anti-obesity agents such as liraglutide [26], curcumin [27] and berberine [25] have been shown to enhance energy expenditure.”
BackgroundQuiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
“promote satiety and thermogenesis by its action in the hypothalamus [58,59].”
BackgroundInfluentialSelf-citationIzaguirre, M., Gómez‐Ambrosi, J., Rodríguez, A., Ramírez, B., Becerril, S., Valentí, V., Moncada, R., Unamuno, X., Silva, C., de la Higuera, M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040479 · Cited by 14
“The increased secretion of GLP-1 has been proposed as one mediator of the increased insulin secretion by pancreatic β-cells [31] but GLP-1 also plays an important role in the regulation of glucose homeostasis [32] or body weight and food intake [33] in other organs, including the central nervous system.”
BackgroundSelf-citationCheng, F., Yuan, G., He, J., Shao, Y., Zhang, J., & Guo, X. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s229838 · Cited by 15
When fat becomes an ally of the enemy: adipose tissue as collaborator in human breast cancer
Lapeire, L., Denys, H. G., Cocquyt, V., & Wever, O. D. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0018 · Cited by 17
Thermogenic Fat as a New Obesity Management Tool: From Pharmaceutical Reagents to Cell Therapies
Cheng, Y., Liang, S., Zhang, S., & Hui, X. H. (2024) · Biomedicines · doi:10.3390/biomedicines12071474 · Cited by 14
“A group of medicines has been demonstrated to activate UCP1 expression levels, including indirubin, rutin, and myricetin [47].”
BackgroundInfluentialIntegration of Glucagon-Like Peptide 1 Receptor Actions Through the Central Amygdala
Duran, M., Willis, J. R., Dalvi, N., Fokakis, Z. N., VIRKUS, S., & Hardaway, J. A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf019 · Cited by 13
Berger, A., Kablan, A., Yao, C., Ho, T., Podyma, B., Weinstein, L. S., & Chen, M. (2015) · Endocrinology · doi:10.1210/en.2015-1700 · Cited by 13
Model, J. F. A., Lima, M. V., Ohlweiler, R., Sarapio, E., Vogt, É. L., Rocha, D. S., de Souza, S. K., & Vinagre, A. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119586 · Cited by 15
Choi, M., Mukherjee, S., & Yun, J. W. (2021) · Phytotherapy Research · doi:10.1002/ptr.7276 · Cited by 13
“Statistical significance is shown as either *p < 0.05 or **p < 0.01 discover novel regulatory molecules and pharmacological interventions (Beiroa et al., 2014; Manigandan & Yun, 2020; Mukherjee, Aseer, & Yun, 2020; Zhang et al., 2014b).”
BackgroundInfluentialSimonds, S. E., Pryor, J. T., Koegler, F. H., Buch-Rasmussen, A. S., Kelly, L. E., Grove, K. L., & Cowley, M. A. (2019) · Diabetes · doi:10.2337/db18-1149 · Cited by 13
“Although we did not assess thermogenesis in these studies, others have demonstrated that liraglutide and GLP-1 receptor activation increases thermogenesis (53,54).”
BackgroundKim, K., & Kim, K. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072296 · Cited by 13
“GLP-1 can additionally increase lipid catabolism via enhancement of β-oxidation or thermogenesis, and also inhibit lipid accumulation via suppression of de novo lipogenesis, leading to improvements of diet-induced obesity and insulin resistance in mice [51,52].”
BackgroundLiu, J., & Lin, L. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.013 · Cited by 13
Progress in the contrary effects of glucagon-like peptide-1 and chemerin on obesity development
Zhang, Q., Ye, J., & Wang, X. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231214270 · Cited by 15
“62 AMPK is an important mediator controlling energy dissipation and a key negative regulator of sympathetically activated BAT thermogenesis, integrating peripheral signals such as thyroid hormone and leptin.”
BackgroundThakur, P., Baraskar, K., Shrivastava, V. K., & Medhi, B. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149176 · Cited by 12
Basdas, R., Martínez-Cereijo, J. M., Fernández, Á. L., Reija, L., Cabaleiro, A., Bravo, S. B., González‐Juanatey, J. R., & Eirás, S. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.03.009 · Cited by 16
Just a Gut Feeling: Central Nervous Effects of Peripheral Gastrointestinal Hormones
Roth, C. L., & Doyle, R. P. (2017) · Endocrine development · doi:10.1159/000475734 · Cited by 12
Loading and firing the brown adipocyte
Hankir, M. K. (2017) · Adipocyte · doi:10.1080/21623945.2017.1405879 · Cited by 14
Incretins: B eyond type 2 diabetes
Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13153 · Cited by 14
Iyer, M. S., Paszkiewicz, R. L., Bergman, R. N., Richey, J. M., Woolcott, O. O., Bediako, I. A., Wu, Q., Kim, S. P., Stefanovski, D., Kolka, C. M., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00539.2018 · Cited by 15
Oh, C., Song, I. H., Lee, W., Jeon, M., Choi, J., Baek, S., Lee, B. C., Kim, S. E., & Im, H. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.10.001 · Cited by 12
Till, A., Fries, C., & Fenske, W. K. (2022) · Brain Sciences · doi:10.3390/brainsci12121646 · Cited by 14
“The hypothalamic expression of GLP-1R significantly contributes to the central role of GLP-1 in regulating BAT thermogenesis in response to the nutrient status but also by browning effects in WAT [66,70,71].”
BackgroundHypothalamic GRP78, a new target against obesity?
Contreras, C., Fondevila, M. F., & López, M. (2017) · Adipocyte · doi:10.1080/21623945.2017.1405878 · Cited by 12
“response several peripheral signals [12-21].”
GLP-1 and Its Role in Glycogen Production: A Narrative Review
Lotosky, J., Jean, X., Altankhuyag, A., Khan, S. R., Bernotas, A., Sharafshah, A., Blum, K., Posner, A. R., & Thanos, P. K. (2025) · Biomedicines · doi:10.3390/biomedicines13071610 · Cited by 17
“In the hypothalamic ventromedial nucleus, GLP-1 acts to increase BAT thermogenesis independent of nutrient intake [110].”
Role of Brown Adipose Tissue in Metabolic Health and Efficacy of Drug Treatment for Obesity
Markina, N. O., Matveev, G. A., Георгиевич, З. Г., Golikova, T. I., Рыжкова, Д. В., Kononova, Y. A., Danilov, S. D., & Babenko, A. Y. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144151 · Cited by 16
“According to experimental studies, the reduction in body weight with GLP-1 receptor agonists’ administration is also associated with the stimulation of BAT thermogenesis and adipose tissue browning [47].”
BackgroundGlucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
“Centrally administered native GLP-1 or GLP-1R agonists acutely and consistently increase whole body energy expenditure in rodents (Beiroa et al. 2014; Kooijman et al. 2015; Lockie et al. 2012; Osaka et al. 2005), presumably by acting on hypothalamic GLP-1Rs and activating downstream sympathetic…”
Zhao, X., Liu, Y., Wang, D., Li, T., Xu, Z., Li, Z., Bai, X., & Wang, Y.-C. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5515 · Cited by 12
“Long‑acting GLP‑1RAs have been shown to influence body weight by modulating food intake and energy expenditure through various hypothalamic pathways (45).”
Suryaningtyas, I. T., Jung, W., Lee, S., & Je, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114844 · Cited by 12
Metadata
- Authors
- Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., Dieguez, C., Lopez, M., Frühbeck, G., & Nogueiras, R.
- Affiliations
- Universidade de Santiago de Compostela (ES)
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- Department of Morphological Sciences, School of Medicine, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- Spanish National Cancer Research Centre (ES)
- Centro de Investigación Biomédica en Red (ES)
- University of Bergen (NO)
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-09-15
- Volume
- 63
- Issue
- 10
- Pages
- 3346-3358
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2108365604
- Cited by
- 602
- References
- 52
- Citations by year
- 2026: 42 · 2025: 63 · 2024: 60 · 2023: 51 · 2022: 57 · 2021: 59 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 43 · 2016: 49 · 2015: 41 · 2014: 8
- FWCI
- 31.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, liraglutide, exenatide, brown adipose tissue thermogenesis, adipocyte browning, ventromedial hypothalamus, AMPK, energy expenditure, food intake regulation, body weight, obesity, type 2 diabetes, central nervous system
- MeSH terms
- Liraglutide, Exenatide, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Adipose Tissue, Brown, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Eating, Energy Metabolism, Female, Humans, Hypoglycemic Agents, Hypothalamus, Male, Metformin, Middle Aged, Obesity, Peptides, Protein Kinases, Venoms, Thermogenesis, Mice, Rats, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.